

Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/medical-industry-feature/evaporative-dry-eye-disease-investigating-treatment-efficacy/32269/>

ReachMD

www.reachmd.com
info@reachmd.com
(866) 423-7849

Evaporative Dry Eye Disease: Investigating Treatment Efficacy

Dr. Rowen:

We're jumping right in to talk about a significant advancement in the treatment of dry eye disease that directly targets tear evaporation.

Dr. Periman:

And of course, we're talking about MIEBO. MIEBO has shown consistent efficacy, providing rapid and sustained improvement across key sign and symptom endpoints, notably in corneal staining and eye dryness.

Dr. Rowen:

We're particularly interested in corneal staining results, as they indicate the healing process of the ocular surface over time.

Dr. Periman:

Indeed. And it's also worth noting that in the clinical trials, every patient had clinical signs of MGD at enrollment, highlighting the applicability of MIEBO for patients with evaporative dry eye.

Dr. Rowen:

Let's talk about the total corneal fluorescein staining, or tCFS, data. This score measures ocular surface damage. And in the MIEBO pivotal trials, rapid and sustained improvement in tCFS scores were seen as quickly as about 2 weeks, with ongoing improvement throughout the end of the trials, or Day 57.

Dr. Periman:

In fact, at Day 57, there was a 2x improvement in total corneal fluorescein staining compared to the control group. And an improvement in central corneal staining, where we saw a 4x improvement versus the control group at Day 57.

Dr. Rowen:

And of course, our primary goal is to help our patients achieve symptom relief from evaporative dry eye disease, and that's why choosing the most appropriate treatment option is so important. With MIEBO, we saw significant improvements in eye dryness, with a 1.5x improvement versus the control group at Day 57.

Based on the consistent, significant improvements in the signs and symptoms of dry eye disease and excellent tolerability profile, MIEBO could be considered a first choice for all appropriate patient types. I think we can agree on that, right?

[On-screen text]

In clinical trials, blurred vision and conjunctival redness were reported in 1% to 3% of patients.

Dr. Periman:

Agreed, and that's something we're definitely seeing eye to eye on.

Announcer:

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO

- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for MIEBO at MIEBO-ECP.COM.